Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001395064-25-000167
Filing Date
2025-12-09
Accepted
2025-12-09 21:02:19
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8318
2 EX-99.1 form13g_exhibit991.htm EX-99.1 1791
3 EX-99.2 form13g_exhibit992.htm EX-99.2 8762
  Complete submission text file 0001395064-25-000167.txt   20587
Mailing Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Business Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 81332782111
TAKEDA PHARMACEUTICAL CO LTD (Filed by) CIK: 0001395064 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13G/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Subject) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90350 | Film No.: 251560620
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)